RETRACTED: Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial(Retracted article. See vol. 40, pg. 103, 2017)

被引:34
作者
Narumi, Hiroya [1 ]
Takano, Hiroyuki [1 ]
Shindo, Satoshi [1 ]
Fujita, Miwa [1 ]
Mizuma, Hiroshi [1 ]
Kuwabara, Yoichi [1 ]
Komuro, Issei [1 ]
机构
[1] Chiba Univ, Dept Cardiovasc Sci & Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan
关键词
angiotensin II receptor blocker; calcium channel blocker; clinical trial; left ventricular hypertrophy; CHRONIC HEART-FAILURE; CONVERTING-ENZYME-INHIBITORS; LEFT-VENTRICULAR HYPERTROPHY; END-POINT REDUCTION; SYMPATHETIC-NERVOUS-SYSTEM; HIGH CARDIOVASCULAR RISKS; RANDOMIZED-TRIAL; LOSARTAN INTERVENTION; MICROALBUMINURIA REDUCTION; DIABETIC-NEPHROPATHY;
D O I
10.1038/hr.2010.186
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Valsartan Amlodipine Randomized Trial, a multicenter, prospective, randomized, open-labeled, blinded-end point trial, was designed to compare the beneficial effects of the angiotensin II receptor blocker valsartan and the calcium channel blocker amlodipine on cardiovascular events in Japanese essential hypertensive patients. The primary end point was a composite of all-cause death, sudden death, cerebrovascular death, cardiac events, vascular events and renal events. The secondary endpoints were effects on left ventricular hypertrophy, cardiac sympathetic nerve activity and renal function. A total of 1021 patients were enrolled in the present trial. The mean follow-up period was 3.4 years. There were no significant differences in blood pressure (BP) levels between the valsartan group and the amlodipine group throughout the trial. There was no significant difference in the primary endpoint between the two groups (hazard ratio: 1.0, P=0.843). No difference in any event category of the primary endpoint was noted for either group. However, we observed a significant reduction of left ventricular mass index, as determined by echocardiography, in the valsartan group compared with the amlodipine group. We also observed a significant decrease in cardiac sympathetic nerve activity in the valsartan group but not in the amlodipine group. Moreover, there was a significant reduction in the urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. Therefore, although BP levels were well controlled and remained equal in the two groups, valsartan had more protective effects on the heart and kidney than amlodipine in Japanese hypertensive patients. Hypertension Research (2011) 34, 62-69; doi: 10.1038/hr.2010.186; published online 7 October 2010
引用
收藏
页码:62 / 69
页数:8
相关论文
共 37 条
[1]  
Andersen S, 2000, KIDNEY INT, V58, P2129
[2]   LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY [J].
BIKKINA, M ;
LEVY, D ;
EVANS, JC ;
LARSON, MG ;
BENJAMIN, EJ ;
WOLF, PA ;
CASTELLI, WP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (01) :33-36
[3]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675
[4]   DETERMINANTS OF SURVIVAL AND LEFT-VENTRICULAR PERFORMANCE AFTER MITRAL-VALVE REPLACEMENT [J].
CRAWFORD, MH ;
SOUCHEK, J ;
OPRIAN, CA ;
MILLER, DC ;
RAHIMTOOLA, S ;
GIACOMINI, JC ;
SETHI, G ;
HAMMERMEISTER, KE .
CIRCULATION, 1990, 81 (04) :1173-1181
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[7]  
Gerstein HC, 2000, DIABETES CARE, V23, pB35
[8]   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].
Granger, CB ;
McMurray, JJV ;
Yusuf, S ;
Held, P ;
Michelson, EL ;
Olofsson, B ;
Östergren, J ;
Pfeffer, MA ;
Swedberg, K .
LANCET, 2003, 362 (9386) :772-776
[9]   Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [J].
Hansson, L ;
Lindholm, LH ;
Ekbom, T ;
Dahlöf, B ;
Lanke, J ;
Scherstén, B ;
Wester, PO ;
Hedner, T ;
de Faire, U .
LANCET, 1999, 354 (9192) :1751-1756
[10]   Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population [J].
Hillege, HL ;
Fidler, V ;
Diercks, GFH ;
van Gilst, WH ;
de Zeeuw, D ;
van Veldhuisen, DJ ;
Gans, ROB ;
Janssen, WMT ;
Grobbee, DE ;
de Jong, PE .
CIRCULATION, 2002, 106 (14) :1777-1782